Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists.
Bigge
C F
CF
Department of Chemistry, Parke-Davis Pharmaceutical Research, Warner-Lambert Co., Ann Arbor, MI 48105.
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D001923:Brain Chemistry; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D015195:Drug Design; D018691:Excitatory Amino Acid Antagonists; D018698:Glutamic Acid; D005998:Glycine / Q000037:antagonists & inhibitors*; D007473:Ion Channels / Q000187:drug effects; D008958:Models, Molecular; D011760:Pyrrolidinones / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000187:drug effects*; D013329:Structure-Activity Relationship
D001643:Bridged Bicyclo Compounds; D018691:Excitatory Amino Acid Antagonists; D007473:Ion Channels; D011760:Pyrrolidinones; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; C001369:1-hydroxy-3-amino-2-pyrrolidone; D005998:Glycine